Maintenance Phase Of Treatment Research Articles

Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine

BackgroundRelapse of major depressive disorder (MDD) is a common clinical problem. This study was designed to determine whether residual sleep disturbance (insomnia and hypersomnia) predict risk of relapse during the continuation and maintenance treatment of MDD.MethodsA total of 570 patients with MDD were treated with open-label, flexible dose fluoxetine (range 20 to 60 mg; mean dose = 45.8 mg/day; SD = 15.1) for 12 weeks. Under double blind conditions, 262 patients who achieved clinical response were randomly assigned to continue fluoxetine or to switch to placebo for 52 weeks or until relapse. Residual sleep disturbance during the baseline visit of the double-blind phase was assessed using items 4, 5, 6 (insomnia) and 22, 23, 24 (hypersomnia) of the Hamilton Depression Rating Scale (HDRS). Survival analysis was utilized to determine the effect of residual sleep disturbance on risk of relapse.ResultsThe severities of early (P > 0.05), middle (P > 0.05), late (P > 0.05), or total (P > 0.05) residual insomnia were not found to significantly predict risk of relapse during continuation and maintenance-phase treatment. Similarly, the severities of early bedtime (P > 0.05), oversleeping (P > 0.05), napping (P > 0.05), or total (P > 0.05) residual hypersomnia were not found to significantly predict risk of relapse during continuation and maintenance-phase treatment.ConclusionThe present study did not identify the severity of residual sleep disturbance among fluoxetine responders to predict risk of MDD relapse. The size of our sample may have precluded us from identifying more modest effects of residual sleep disturbance on the risk of relapse in MDD patients. Future studies are needed to further explore the relationship between residual sleep disturbance and relapse in MDD.Trial RegistrationClinicalTrials.gov Identifier: NCT00427128

Mass Spectrometric Analyses of Peptides and Proteins in Human Gingival Crevicular Fluid

Gingival crevicular fluid (GCF) is a pathophysiological fluid that flows into the oral cavity. Human GCF was collected using sterile glass microcapillary tubes from inflamed periodontal sites in patients who had a history of periodontal disease and were in the maintenance phase of treatment. Samples from individual sites were analyzed using MS techniques both before and following HPLC. GCF samples were also pooled and subjected to SDS-PAGE, in-gel digestion and MS analyses using both MALDI-TOF/TOF MS and nanoLC-ESI-MS/MS. MS spectra were used to search human protein sequence databases for protein identification. With these approaches, 33 peptides and 66 proteins were positively identified in human GCF. All of the peptides discovered in this study are reported in GCF here for the first time. Forty-three of the identified proteins, such as actin and the actin binding proteins profilin, cofilin and gelsolin, have not been reported in GCF before.

Experimental evaluation of behavioral activation treatment of anxiety (BATA) in three older adults.

This report describes three single-case experimental evaluations of Behavioral Activation Treatment of Anxiety (BATA) applied with a 51-year-old male, a 62-year-old female, and a 53-year-old female, each of whom met DSM-IV criteria for anxiety. Each case was a clinical replication of an initial trial of BATA reported in Turner and Leach (2009). Treatment was delivered in twelve weekly 60-minute individual sessions and evaluated using an A-B-C phase change with repeated measurement design. Decreased scores in self-reported anxiety were obtained in each case and the improvements were maintained during a 3-month no treatment maintenance phase. Compared to baseline, each participant also recorded increases in activity levels in some key life areas during the treatment phase. These preliminary findings suggest that increased activation in functionally positive areas is associated with reported decreases in anxiety and that BATA could be an effective stand-alone treatment for anxiety in adults.

Diagnosis and Treatment of a Major Depressive Episode

A thorough evaluation should be conducted before diagnosing and treating major depressive disorder. Research suggests that augmentation of antidepressant pharmacotherapy from the start of treatment may be more efficacious than antidepressant monotherapy. Clinical implementation of objective measurement tools is recommended for the assessment of treatment outcomes. These strategies may increase the likelihood of patient remission and continued wellness during the continuation and maintenance phases of treatment.

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

In this prospective cohort study, we have undertaken a comprehensive evaluation of clinical parameters along with variation in 29 genes (including CYP2C9 and VKORC1) to identify factors determining interindividual variability in warfarin response. Consecutive patients (n=311) were followed up prospectively for 26 weeks. Several outcomes chosen to capture both warfarin efficacy and toxicity were assessed. Univariate and multiple regression analyses were undertaken to assess the combined effect of clinical and genetic factors. CYP2C9 was the most important gene determining initial anticoagulant control, whereas VKORC1 was more important for stable anticoagulation. Novel associations with some clinical outcomes were found with single nucleotide polymorphisms in the cytochrome 450 genes CYP2C18 and CYP2C19, which were independent of the associations observed with CYP2C9 and in genes encoding CYP3A5, protein S and clotting factor V, although the variability explained by these genes was small. On the basis of the results of microcosting, adverse events were shown to be a significant predictor of total cost. Accurate prediction of warfarin dose requirement needs to take into account multiple genetic and environmental factors, the contributions of which vary in the induction and maintenance phases of treatment.

Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose – response relationships

Background: Enzyme therapy for Gaucher disease has improved the lives of many patients, by reducing the burden of their disease. Several studies have sought to determine to what extent optimal clinical outcomes are a function of the prescribed enzyme dose and its resultant costs. Objective: Issues concerning dose – response relationships during initial and maintenance treatment phases and currently applied treatment goals have been addressed. Methods: All studies that aimed to describe the efficacy of different doses of treatment and approaches for maintenance, such as lowering the dose or changing to less frequent infusions and the effects of drug interruptions, were reviewed. Results/conclusion: Dose – response relationships do exist, but doses between 30 and 60 U/kg per month may be sufficient in a large majority of patients. Goals of treatment should include important clinical end points, such as enhanced quality of life and decreased risk for malignancies and other morbidities. The relationship between these important end points and treatment schedules deserve further study.

Brief Behavioural Activation Treatment of Chronic Anxiety in an Older Adult

AbstractA 64-year-old male who met criteria for social and generalised anxiety was treated using a brief behavioural activation (BA) approach. The intervention was delivered in twelve weekly 60-minute individual sessions. The effects of the intervention were assessed using a simple A-B-C phase change with repeated measurement design. Change in reported anxiety was recorded across phases. Decreased scores in self-reported anxiety measures were obtained and significant clinical improvement was maintained during a 4-month no treatment maintenance phase. This preliminary investigation suggests BA could be an efficient and effective treatment for anxiety and that replications are warranted.

Community Views on Cutaneous Leishmaniasis in Istalif, Afghanistan: Implications for Treatment and Prevention

Afghanistan currently has the world's largest outbreak of Cutaneous Leishmaniasis with more than 9% of the population (270,000) of Kabul affected. Transmitted through the bite of a sandfly, this disfiguring skin disease causes ulcerous lesions and permanent scarring. Physical, social, and economic consequences of the disease among those affected, their families, and communities are severe. Current control programs consist of both treatment and prevention. A clear understanding of the underlying factors influencing people's treatment-seeking behavior and utilization of prevention methods is critical for program success. However, these factors have not been well established. This article investigates illness recognition and treatment-seeking behavior, beliefs about etiology and transmission of the disease, and views of prevention and protection among the population of Istalif, a district in theKabul Province. The knowledge, attitudes, and preferences of participants in the focus groups highlight barriers to current control efforts, as well as opportunities for behavior change. An intervention strategy is proposed based on the analysis of these factors and includes an attack phase of treatment to reduce the infective human reservoir, lower morbidity, and distribution of Long-Lasting Insecticide Nets to interrupt the transmission cycle. This is followed by a maintenance phase of treatment, vector control, individual protection, health education, promotion, and community mobilization.

Long-acting risperidone: a review of its role in the treatment of bipolar disorder

Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.

Mass Antibiotic Treatment Alone Does Not Eliminate Ocular Chlamydial Infection

Mass Antibiotic Treatment Alone Does Not Eliminate Ocular Chlamydial Infection

Changes Over Time and Disparities in Schizophrenia Treatment Quality

Schizophrenia medication and psychosocial treatment options have expanded since the Schizophrenia PORT was conducted. However, there also have been considerable changes in the delivery of mental health care in the public sector, as well as increasing state concerns about Medicaid cost containment. To examine trends and patient characteristics associated with differences in schizophrenia medication and visit treatment quality in a Medicaid population. Observational study of claims data from July 1, 1996 to June 30, 2001. Florida Medicaid enrollees diagnosed with schizophrenia (N = 23,619). We examined the likelihood of meeting any 1 and all 4 of the following quality standards: (1) receiving antipsychotic medication, (2) antipsychotic continuity, (3) dosing consistent with PORT recommendations, and (4) mental health visit continuity. Separate models were fit for acute and maintenance phases of treatment. Approximately 18% of acute and 7% of maintenance phases met all 4 quality standards. Antipsychotic quality improved (largely driven by an increasingly likelihood of receiving any antipsychotic), while visit continuity declined. The greatest disparities were seen for persons with co-occurring substance use disorders and of black race. Quality differences were often phase specific and at times in opposite directions across treatment phases. The improvement in antipsychotic treatment quality is encouraging. However, visit continuity declined. This study highlights the importance of quality measurement that includes focus on different treatment modalities and phases of care, as well as for potentially vulnerable populations (such as persons with co-occurring substance use disorders and racial/ethnic minorities).

Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) para tratamento biológico de transtornos depressivos unipolares, 2ª parte: tratamento de manutenção do transtorno depressivo maior e tratamento dos transtornos depressivos crônicos e das depressões subliminares

These practice guidelines for the biological treatment of unipolar depressive disorders were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal for developing these guidelines was to systematically review all available evidence pertaining to the treatment of the complete spectrum of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating patients with these conditions. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for depressive disorders, as well as from meta-analyses and reviews on the efficacy of antidepressant medications and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and was then categorized into four levels of evidence (A-D). The first part of these WFSBP guidelines on unipolar depressive disorders covered the acute and continuation treatment of major depressive disorder (Bauer et al., 2002). This second part of the guidelines covers the management of the maintenance-phase treatment of major depressive disorder, as well as the treatment of chronic and subthreshold depressive disorders (dysthymic disorder, double depression, minor depressive disorder and recurrent brief depression). These guidelines are primarily concerned with thebiological treatment (including antidepressants, lithium, other psychopharmacological and hormonal medications, and electroconvulsive therapy) of young adults and also, albeit to a lesser extent, children, adolescents and older adults.

Eculizumab Therapy Results in Rapid and Sustained Decreases in Markers of Thrombin Generation and Inflammation in Patients with PNH

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disorder of the bone marrow resulting from an acquired mutation in the PIG-A gene. The mutation decreases production of the glycosylphosphatidylinositol membrane anchor for a variety of membrane proteins. Loss of cell membrane CD59 and CD55 results in enhanced complement-mediated cell membrane injury. PNH is associated with an increased risk of venous (VTE) and arterial thrombosis. Eculizumab, a monoclonal antibody to complement C5, has received FDA approval for the treatment of PNH. Recent published data demonstrates a 92% reduction in thrombotic events with the use of eculizumab. However, the mechanism for this reduction is unclear. We have enrolled eight PNH patients (pts) in an ongoing IRB-approved study on the effect of eculizumab treatment on markers of thrombin generation and inflammation. Patients were treated by the FDA-approved treatment protocol with blood samples obtained prior to treatment day 1 and prior to each dose on days 8, 15, 22, 29, 43 and 90. Patients receiving anticoagulants and corticosteroids were continued on their baseline medications. Plasma samples were assayed for D-dimers (D-D), thrombin-antithrombin complex (TAT), interleukin 6 (Il-6) by ELISA and tissue factor microparticles (TFMP) by impedance-based flow cytometry. Mean age of pts was 40.8 years (26–70); 6 male pts and 2 females. One patient had a prior history of VTE; 4 pts were receiving anticoagulants (1 full dose low molecular weight heparin (LMWH), 2 prophylactic LMWH, 1 warfarin) and 2 pts were receiving prednisone at the initiation of eculizumab. The effect of eculizumab on markers of hemostatic activation and inflammation was evaluated using Wilcoxon signed-rank test and multilevel models.Results: Pretreatment levels of D-D were significantly elevated in all but two of the patients who were receiving anticoagulants. Pretreatment Il-6 levels were significantly elevated in all but two patients taking prednisone. With eculizumab treatment, there was a statistically significant decrease in LDH (p=0.0001), D-D (p=0.0057), TAT (0.0138) and Il-6 (p=0.0362) during the 4 week induction phase of treatment (days 1–29). TAT levels significantly decreased by day 8 (p=0.008), with little subsequent change to day29 and day 90. All decreases in D-D, TAT, Il-6 and LDH were sustained in the maintenance phase of treatment (days29–90). Plasma TFMP were detectable and significantly increased in all patients prior to treatment. There was a statistically significant decrease in TFMP by day 8 (p=0.0234) and TFMP levels remained below pretreatment levels for the duration of the study (p=0.030). However, there were wide individual variations in TFMP levels over the course of treatment. There were significant Spearman correlations between changes in D-D and TAT (0.521; p<0.0001), in D-D and IL-6 (0.4400; p=0.0007). Changes in LDH did not correlate with changes in D-D, TAT, TFMP or Il-6. Changes in TFMP did not correlate with changes in markers of thrombin generation (TAT or D-D).Conclusion: Eculizumab treatment of patients with PNH results in a rapid decrease in plasma tissue factor microparticles, thrombin generation and inflammation. These changes appear to be independent of eculizumab suppression of RBC hemolysis as characterized by decreases in serum LDH. A direct relationship between plasma TFMP levels and thrombin generation in PNH patients could not be confirmed in this study. Taken together, these data indicate the broader impact of eculizumab treatment to suppress inflammation and prothrombotic activity in patients with PNH.

Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants

This meta-analysis reviewed data on the efficacy and effectiveness of second-generation antidepressants for preventing major depression relapse and recurrence during continuation and maintenance phases of treatment, respectively. MEDLINE, EMBASE, and PsycINFO, the Cochrane Library, and International Pharmaceutical Abstracts were searched for the period of January 1980 through April 2007 for reviews, randomized controlled trials, meta-analyses, and observational studies on the topic. Two persons independently reviewed abstracts and full-text articles using a structured data abstraction form to ensure consistency in appraisal and data extraction. Four comparative trials and 23 placebo-controlled trials that addressed relapse or recurrence prevention were included. Results of comparative trials have not demonstrated statistically significant differences between duloxetine and paroxetine, fluoxetine and sertraline, fluvoxamine and sertraline, and trazodone and venlafaxine. Pooled data for the class of second-generation antidepressants compared with placebo suggested a relatively large effect size that persists over time. For preventing both relapse and recurrence, the number of patients needed to treat is five (95% confidence interval of 4 to 6). Differences in the length of open-label treatment before randomization, drug type, and trial duration did not affect pooled estimates of relapse rates. Across all trials, 7% of patients randomly assigned to receive active treatment and 5% of patients randomly assigned to receive a placebo discontinued treatment because of adverse events. This review demonstrates the overall benefits of continuation- and maintenance-phase treatment of major depression with second-generation antidepressants and emphasizes the need for additional studies of comparative differences among drugs.

Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants

This meta-analysis reviewed data on the efficacy and effectiveness of second-generation antidepressants for preventing major depression relapse and recurrence during continuation and maintenance phases of treatment, respectively. MEDLINE, EMBASE, and PsycINFO, the Cochrane Library, and International Pharmaceutical Abstracts were searched for the period of January 1980 through April 2007 for reviews, randomized controlled trials, meta-analyses, and observational studies on the topic. Two persons independently reviewed abstracts and full-text articles using a structured data abstraction form to ensure consistency in appraisal and data extraction. Four comparative trials and 23 placebo-controlled trials that addressed relapse or recurrence prevention were included. Results of comparative trials have not demonstrated statistically significant differences between duloxetine and paroxetine, fluoxetine and sertraline, fluvoxamine and sertraline, and trazodone and venlafaxine. Pooled data for the class of second-generation antidepressants compared with placebo suggested a relatively large effect size that persists over time. For preventing both relapse and recurrence, the number of patients needed to treat is five (95% confidence interval of 4 to 6). Differences in the length of open-label treatment before randomization, drug type, and trial duration did not affect pooled estimates of relapse rates. Across all trials, 7% of patients randomly assigned to receive active treatment and 5% of patients randomly assigned to receive a placebo discontinued treatment because of adverse events. This review demonstrates the overall benefits of continuation- and maintenance-phase treatment of major depression with second-generation antidepressants and emphasizes the need for additional studies of comparative differences among drugs.

Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain

Background and objectives:Opioid-induced constipation can have a major negative impact on patients’ quality of life. This randomised clinical trial evaluated patient assessment of the efficacy and tolerability of oral prolonged-release (PR) oxycodone when co-administered with oral naloxone PR.Methods:Two hundred and two patients with chronic cancer- or non-cancer-related pain undergoing stable oxycodone PR therapy (40, 60 or 80 mg/day) were randomised to one of four intervention groups: 10, 20 or 40 mg/day naloxone PR or placebo. Following a 4-week maintenance phase, patients were followed-up for 2 weeks in which time they received oxycodone PR only. At the end of the maintenance phase, patients and investigators were asked to assess treatment efficacy and tolerability, as well as preference for the titration or maintenance phase.Results:Patient and investigator global assessment of efficacy and tolerability improved with increasing naloxone dose. Efficacy was ranked as ‘good’ or ‘very good’ by 50.0%, 67.4% and 72.5% of patients in the 10, 20 and 40 mg naloxone PR dose groups, respectively, compared with 43.5% of patients in the placebo group. Patient assessment of tolerability was similar between treatment groups and placebo, being ranked as ‘good’ or ‘very good’ by 83.3%, 79.1% and 82.5% of patients in the 10, 20 and 40 mg/day naloxone PR dose groups, respectively, compared with 71.7% of patients in the placebo group. The maintenance treatment phase was preferred by patients in the naloxone groups. A 2 : 1 dose ratio of oxycodone to naloxone was also assessed. Efficacy was ranked as ‘good’ or ‘very good’ by 70.4% of patients treated with the 2 : 1 dose ratio compared with 43.5% of patients receiving placebo. Tolerability of the 2 : 1 dose ratio was ranked as being ‘good’ or ‘very good’ by 81.5% of patients compared with 71.1% for the placebo group and patients preferred the maintenance phase.Conclusions:The co-administration of oral naloxone PR with oxycodone PR improves patient assessment of analgesic opioid therapy for severe chronic pain, in terms of both efficacy and tolerability.

Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study

The aim of this study was to assess the efficacy and safety of esomeprazole 40 mg once daily (q.d.) in healing reflux oesophagitis at 4 and 8 weeks, and the efficacy of esomeprazole 20 mg q.d. for 12 weeks in the maintenance of remission. A total of 235 patients with endoscopically proven reflux oesophagitis were enrolled in this study, which consisted of two phases (healing and maintenance therapy). Patients who showed complete endoscopic and symptomatic healing at the end of 4 or 8 weeks were switched to maintenance treatment with esomeprazole 20 mg q.d. for 12 weeks. The primary efficacy endpoint was healing of reflux oesophagitis at week 8. Secondary assessments included the proportion of patients with symptomatic relapse in the maintenance phase. At the end of week 8, 88% (95% life-table confidence intervals [CI]: 84%, 92%) of patients were healed endoscopically and 90.6% of the patients were asymptomatic. Patient age, gender and Helicobacter pylori status had no effect on the efficacy of treatment. During the 12-week maintenance treatment phase, symptomatic relapse ratios were 0.5%, 2.2%, and 0%, for the first, second, and third 4-week periods, respectively. The proportions of patients satisfied with treatment were 95% and 99.4% at the end of acute and maintenance treatment, respectively. The most common adverse effects were headache, upper respiratory tract infection and abdominal pain. Esomeprazole is effective in the healing of reflux oesophagitis, the resolution of heartburn, and in maintaining symptomatic remission. The effectiveness of esomeprazole in patients with gastroesophageal reflux disease is not affected by the presence of H. pylori.

Creatine monohydrate attenuates body fat accumulation in children with acute lymphoblastic leukemia during maintenance chemotherapy

Corticosteroids are an important component of the treatment of acute lymphoblastic leukemia (ALL), with known significantly negative effects on bone and muscle. Creatine monohydrate (CrM) supplementation may be an adjunctive therapeutic strategy to attenuate some of these adverse effects. Nine children with ALL in the maintenance phase of treatment on the Dana-Farber Cancer Institute (DFCI) protocol 2000-2001 were treated with CrM (0.1 g/kg/day) for two sequential periods of 16 weeks (16 weeks treat > 6 weeks wash-out > 16 weeks treat). A cohort of children (N = 50) who were receiving the same chemotherapy at the same time served as natural history controls. Measurements included height, weight, body mass index (BMI), and lumbar spine bone mineral density (LS-BMD), whole body bone mineral content (WB-BMC), fat-free mass (FFM), and percent body fat (%BF) using dual-energy X-ray absorptiometry. Despite the long course of corticosteroid treatment for ALL, children showed significant increases in height, LS-BMD, WB-BMC and FFM over approximately 38 weeks (P < 0.05) during the study. There was an increase in BMI over time, but children taking CrM had a reduction, while the natural history group showed an increase in % BF (P < 0.05 for interaction). Children with ALL treated with corticosteroids as part of a maintenance protocol of chemotherapy showed an increase in % BF that was attenuated by CrM supplementation.

Treating Schizophrenia With Comorbid Depressive or Demoralization Symptoms

Article AbstractBecause this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.Sir: Two of us (I.D.G., J.M.D.) recently had an articlepublished in the Journal1 which suggested that concomitantpsychotropic medications (CPMs) may not improve outcomeof antipsychotic monotherapy for stabilized patients withnonacute schizophrenia. In the article, we stated that "to ourknowledge, there have been no published reports of prospectiveinvestigations of systematic discontinuation of concomitantmedication in this patient population (i.e., nonacute,stabilized patients with schizophrenia)."1(p1262)As it happens, one prospective, double-blind, randomized,controlled study of the discontinuation of adjunctive antidepressantmedication, during maintenance-phase treatment hadbeen conducted.2†‹†‹

The cumulative impact of nonsevere life events predicts depression recurrence during maintenance treatment with interpersonal psychotherapy.

Although much research has focused on the role of severe life events as risk factors for depression onset, less is known about the relationship between nonsevere life events and depression recurrence. The current study examined the cumulative effects of nonsevere and positive life events on depression recurrence in an outpatient sample of recurrently depressed women treated to remission with interpersonal psychotherapy (IPT). A Cox proportional hazards model was used to test this relationship in 124 adult women who entered into the maintenance phase of IPT treatment and completed at least 1 Life Events and Difficulties Schedule interview. The cumulative experience of nonsevere life events that were subject- or joint-focused and nonindependent was significantly related to depression recurrence during the maintenance treatment phase. None of the other event categories were significantly related to depression recurrence. These findings may help to clarify the mechanisms by which life events contribute to depression recurrence and to guide the development of more efficacious maintenance treatments.